A vaccine for the common and sometimes deadly RSV (respiratory syncytial virus) has been elusive, but scientists say a new discovery puts them much closer to success. A new study from The Ohio State University provides a potential blueprint for finding the immunological sweet spot – a vaccine weak enough that it doesn’t make people sick but strong enough that it prompts an ample immune response, ensuring that the body will recognize RSV as an intruder in the future, and quickly mount a protective defense. In a study published in the journal Nature Communications, researchers report success in knocking out an epigenetic modification known as N6-methyladenosine in RSV RNA – a technique that proved to tamp down the virus and prompt a robust immune response in cotton rats. “We now have a novel target to go after, and are working with industry toward a vaccine,” said the study’s senior author, Jianrong Li, an...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!




